Humacyte, Inc. (HUMA), a biotechnology company specializing in bioengineered human tissues, on Friday, announced that the FDA has granted full approval for SYMVESS (acellular tissue-engineered vessel) for use as a vascular conduit in extremity arterial injury.
This approval follows the program's Regenerative Medicine Advanced Therapy (RMAT) designation in May 2023 and a Priority Review granted in February 2024. The BLA was submitted in December 2023.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com